Drug Screening Using Stem Cell Technology

Year : 2025 | Volume : 12 | Issue : 03 | Page : 42 51
    By

    Bandhakavi Sai Ashish,

  • Harshini Gangadhara,

  • Enjula Uchoi,

  • Varsha Myaka,

  • Nirbhay Kumar Pandey,

  1. Student, Department of Computer Science and Engineering Lovely Professional University Jalandhar, Punjab, India
  2. Student, Department of Computer Science and Engineering Lovely Professional University Jalandhar, Punjab, India
  3. Student, Department of Computer Science and Engineering Lovely Professional University Jalandhar, Punjab, India
  4. Student, Department of Computer Science and Engineering Lovely Professional University Jalandhar, Punjab, India
  5. Student, Department of Computer Science and Engineering Lovely Professional University Jalandhar, Punjab, India

Abstract

Stem cell technology in drug screening has transformed the research and development sector of pharmaceuticals. Although stem cells imitate their human counterparts in terms of both safety and potential, it is a new paradigm for mimicking diseases of humans and scale measuring for toxicity. These tissues will, therefore, be more predictive of what will happen in humans during clinical situations, compared to conventional cell lines or animal models, since they can model human-specific cellular responses. They’re particularly useful in studying complex diseases like cancer, cardiovascular disease, and neurodegenerative diseases, where animal models frequently fall short in fully replicating human pathophysiology. It might even allow for personalized therapy in finding individualized treatment out of patient-derived cells. A couple of obstacles still need some assistance; for instance, stem cell culture is extremely expen- sive, differentiation techniques are very tenuous, and models need robust validation before the differentiation. Even though restrictions hinder their practice, automated high-throughput and gene-editing technologies slowly yet steadily ambled past those barriers and thereby have placed drug discovery onto an advanced and reliable lane. Stem cell technology is going to revolutionize drug screening from a total dimension by improving preclinical precision, reducing the dependence on animal models, and speeding up the process of producing safer and better cures.

Keywords: Stem cells, drug screening, toxic compounds, reproductive toxicity, convolutional neural networks.

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

How to cite this article:
Bandhakavi Sai Ashish, Harshini Gangadhara, Enjula Uchoi, Varsha Myaka, Nirbhay Kumar Pandey. Drug Screening Using Stem Cell Technology. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(03):42-51.
How to cite this URL:
Bandhakavi Sai Ashish, Harshini Gangadhara, Enjula Uchoi, Varsha Myaka, Nirbhay Kumar Pandey. Drug Screening Using Stem Cell Technology. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(03):42-51. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=225141


References

  1. Liang, Ping, et al. ”Drug screening using a library of human induced pluripotent stem cells–derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.” Circulation 127.16 (2013): 1677-1691.
  2. Shaheen, N., A. Shiti, and L. Gepstein. ”Pluripotent stem cell-based platforms in cardiac disease modeling and drug testing.” Clinical Phar- macology Therapeutics 102.2 (2017): 203-208.
  3. Shinozawa, Tadahiro, et al. ”High-fidelity drug-induced liver injury screen using human pluripotent stem cells–derived organoids.” Gastroen- terology 160.3 (2021): 831-846.
  4. Yang, Liuliu, et al. ”A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids.” Cell stem cell 27.1 (2020): 125-136.
  5. Egawa, Naohiro, et al. ”Drug screening for ALS using patient-specific induced pluripotent stem cells.” Science translational medicine 4.145 (2012): 145ra104-145ra104.
  6. Higgins, J. William, et al. ”Bioprinted pluripotent stem cell-derived kidney organoids provide opportunities for high content screening.” bioRxiv (2018): 505396.
  7. Martinez-Romero, M., et al., Artificial intelligence techniques for colorectal cancer drug metabolism: ontologies and complex networks. Current drug metabolism, 2010. 11(4),p: 347-368.
  8. Yang, X., et al., Concepts of artificial intelligence for computer-assisted drug discovery. Chemical reviews, 2019. 119(18).p: 10520- 10594.
  9. Ezziane, Z., Applications of artificial intelligence in bioinformatics: A review Expert Systems with Applications, 2006.
  10. Narayanan, A., E.C. Keedwell, and B. Olsson, Artificial intelligence techniques for bioinformatics. Applied bioinformatics, 20021,p:191-222.
  11. Nicolas, J., Artificial intelligence and bioinformatics,in A Guided Tour of Artificial Intelligence Research. 2020, Springer, p: 209-264.
  12. Bulow, R.D., et al. How will artificial intelligence and bioinformatics change our understanding of IgA in the next decade in Seminars in Immunopathology 2021. Springer.
Regular Issue Subscription Review Article
Volume 12
Issue 03
Received 20/08/2025
Accepted 25/08/2025
Published 29/08/2025
Publication Time 9 Days
216

Login


My IP

PlumX Metrics